UNSPSC 51171834: Cannabinol or nabiximols or tetrahydrocannabinol

This classification denotes an antiemetic agent with the molecular formula C21H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UYP6MC9GH, chemically known as 6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol but generally known as cannabinol, which bears US NIH Compound Identifier 2543. Cannabinol most often comes in base, methyl, and tert-butyldimethylsilyl ether forms. European Medicines Agency schedules Cannabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06074MIG.

UNSPSC 51171834 Cannabinol or nabiximols or tetrahydrocannabinol is a Commodity code that nominally covers controlled cannabinoid substances, yet recent state and local opportunities show no direct procurement of these products. Instead, the code appears in the context of drug testing services and pharmaceutical supply chain management, which represent significant operational misalignments with the code's core scope. The most active recent solicitation under this code involves specimen collection and drug testing services rather than the purchase of cannabinoid products themselves, indicating either misclassification in state and local procurement systems or use of the code as a catch-all for drug-related commodities beyond its strict definition.

Activity concentrates in Texas, where Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and estimated contract value of $600,000 over two years with optional renewals. That solicitation encompasses staffing collection sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies including oral fluid and hair testing, with annual testing demand of approximately 25,031 tests. Texas Health and Human Services Commission also posted Request for Information HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing preliminary market research rather than a formal procurement. Minnesota's multistate cooperative purchasing vehicle MMCAP issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers across state and local government facilities in multiple states including Oregon. The code shows fragmented issuing-body participation across state criminal justice, health and human services, and cooperative purchasing entities, with no evidence of direct cannabinoid procurement activity in current state and local markets.